hrp0095p1-547 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Project to improve paediatric post-neurosurgical fluid management and to reduce the risks associated with Diabetes Insipidus (DI), Syndrome of Inappropriate ADH (SIADH) and Cerebral Salt Wasting (CSW).

Miller-Molloy Felix , Saxena Shreya , Bowen Philippa , Fellows Greg , Crowne Liz

Background: Complex fluid balance problems are well established post-neurosurgery and traumatic brain injury (TBI). The triple-phase response requires fluid management strategies reactive to urine output as patients shift between DI and SIADH. Prevalence of CSW is controversial; but ensuring sodium homeostasis is central to safe fluid management. To improve clinical care for these complex patients an audit of existing institutional guidelines was undertaken. N...

hrp0092p2-22 | Adrenals and HPA Axis | ESPE2019

An Atypical Case of Ectopic ACTH Syndrome in an Adolescent Boy

Sharma Shreya , Joshi Rajesh

Background: Ectopic ACTH syndrome (EAS) is exceedingly rare in children and scarcely reported. Pancreatic Neuroendocrine tumours (NET) can rarely lead to secretion of ectopic adrenocorticotropic hormone (ACTH).Case Characteristics: A14-year-old adolescent boy presented with isolated hyperpigmentation and intermittent abdominal pain and underwent evaluation for primary adrenal insufficiency, but turned out to have subclin...

hrp0092p1-62 | Fat, Metabolism and Obesity | ESPE2019

Short-term Treatment of Liraglutide in Patient with Prader-Willi Syndrome

Cheon Chong Kun , Yoon Ju Young , Choi Im Jeong , Kim Hyun-Ji

Background: Prader-Willi syndrome (PWS) is a genetic disorder associated with developmental delay, obesity, and obsessive behavior related to food consumption. Treatment options for weight control in those patients is limited and there are controversies for a surgical approach. Saxenda® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with obes...

hrp0095p1-482 | Fat, Metabolism and Obesity | ESPE2022

Liraglutide SC in the treatment of severe obesity in Pediatrics: a missed therapeutic opportunity?

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , Jose Espina-Diez Mari

Liraglutide 3.0 mg has been shown to improve body mass index (BMI) and weight in obese adolescents. And it has done so in a randomized, double-blind, phase 3 clinical trial that has investigated the effect of liraglutide 3mg. compared with placebo for weight control in 251 obese minors, and as a complement to a healthy lifestyle. Adverse events associated with the use of liraglutide 3.0 in pediatric patients are not very different from those observed in adults. There may be ca...